RLD strength for BE study [Design Issues]

posted by Brus – Spain, 2021-01-21 15:24 (682 d 23:51 ago) – Posting: # 22186
Views: 1,455

Dear Colleagues,

We are developing a generic of an RLD with two strengths (100 mg and 50 mg).

But viewing the dosage regimen of reference drug product, it would make sense to develop a 150 mg strength even though the reference product does not have it. So, our generic drug product will have 3 strengths (150, 100 and 50 mg).

What dose should the BE study be done with? (PK linearity has been demonstrated in the range of that doses).

Should RLD 100mg VS Generic 100mg be done or RLD 100mg + RLD 50mg VS generic 150mg?

Best regards,

Complete thread:

UA Flag
Activity
 Admin contact
22,428 posts in 4,694 threads, 1,598 registered users;
15 visitors (0 registered, 15 guests [including 8 identified bots]).
Forum time: 15:16 CET (Europe/Vienna)

Statistics is the art of never having to say you’re wrong.
Variance is what any two statisticians are at.    C.J. Bradfield

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5